PREVIEW

NPA Warns of Surge in Fake Weight Loss Injections Amid Ozempic Shortages. The National Pharmacy Association (NPA) has issued a warning against purchasing fake weight loss injections, amid ongoing Ozempic shortages expected to last into next year, Sky News reports. The NPA cautions about a potential rise in unlicensed sales of Ozempic and Wegovy online, urging the public to avoid these due to health risks. Originally for type 2 diabetes, Ozempic has gained popularity for its appetite-suppressing properties, leading to high demand and shortages. Social media has fueled the popularity of Ozempic and Wegovy, with numerous before-and-after weight loss posts and celebrity endorsements. UK pharmacists are experiencing significant shortages of Ozempic, exacerbated by some doctors prescribing it off-label for obesity. The NPA advises patients to consult pharmacists or GPs rather than buying medicines from unregistered online sellers, highlighting the risks involved. NPA chairman Nick Kaye expressed deep concern over depleted stocks of Ozempic and urged prioritizing supplies for those in critical need. In January, the Department of Health and Social Care advised against off-label prescribing of Ozempic for weight loss, stressing the need to reserve stocks for diabetes patients. The World Health Organization and the US FDA have both warned about the dangers of counterfeit semaglutide, citing reports of severe side effects from overdoses. The NPA calls for public vigilance, recommending checks to ensure online providers are registered and urging a crackdown on unauthorized online medicine sales.
Instructions: THIS VIDEO MUST NOT BE EDITED FOR LENGTH TO COMBINE WITH OTHER CONTENT